Misplaced Pages

Zidovudine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 22:15, 28 July 2011 editLuckas-bot (talk | contribs)929,662 editsm r2.7.1) (robot Adding: hu:Zidovudin← Previous edit Latest revision as of 07:29, 30 November 2024 edit undoWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers48,627 edits EML 
(578 intermediate revisions by more than 100 users not shown)
Line 1: Line 1:
{{Short description|Antiretroviral medication}}
{{Redirect|AZT}} {{Redirect|AZT}}
{{cs1 config|name-list-style=vanc}}
{{drugbox | Verifiedfields = changed
{{Use mdy dates|date=July 2023}}
{{infobox drug
| Verifiedfields = changed
| Watchedfields = changed | Watchedfields = changed
| verifiedrevid = 402376661 | verifiedrevid = 441946513
| drug_name =
|fat
| IUPAC_name = 1--5-methylpyrimidine-2,4-dione<ref>{{cite web |url=http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=35370 |title=Zidovudine |work=PubChem Public Chemical Database |publisher=NCBI |accessdate=2011-04-10 }}</ref>
| image = Zidovudine.svg | image = Zidovudine.svg
| alt =
| image2 = Zidovudine-3D-balls.png
| width = 155
| CASNo_Ref = {{cascite|correct|CAS}}
| image2 = Zidovudine-from-xtal-3D-bs-17.png
| alt2 =

<!--Clinical data-->
| tradename = Retrovir, others
| Drugs.com = {{drugs.com|monograph|zidovudine}}
| MedlinePlus = a687007
| DailyMedID = Zidovudine
| pregnancy_AU = B3
| licence_EU = yes
| routes_of_administration = ], ], ]
| ATC_prefix = J05
| ATC_suffix = AF01

<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = POM
| legal_UK_comment = <ref>{{cite web | title=Retrovir 100mg Capsules – Summary of Product Characteristics (SmPC) | website=(emc) | date=December 14, 2018 | url=https://www.medicines.org.uk/emc/product/6811/smpc | access-date=January 23, 2021}}</ref>
| legal_US = Rx-only
| legal_US_comment = <ref>{{cite web | title=Retrovir – zidovudine capsule Retrovir – zidovudine solution Retrovir – zidovudine injection, solution | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6df09f15-b102-431c-adde-d7aeef6f5d84 | access-date=January 23, 2021}}</ref>
| legal_EU = Rx-only
| legal_EU_comment = <ref>{{cite web | title = Active substance: Zidovudine | url = https://www.ema.europa.eu/en/documents/psusa/zidovudine-list-nationally-authorised-medicinal-products-psusa/00003143/201703_en.pdf | work = European Medicines Agency | date = November 30, 2017 }}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment =
| legal_status = Rx-only

<!--Pharmacokinetic data-->
| bioavailability = Complete absorption, following first-pass metabolism systemic availability 75% (range 52 to 75%)
| protein_bound = 30 to 38%
| metabolism = ]
| elimination_half-life = 0.5 to 3 hours
| excretion = ] and ]

<!--Identifiers-->
| IUPHAR_ligand = 4825
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 30516-87-1
| PubChem = 35370
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00495
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 32555
| NIAID_ChemDB = 000001
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4B9XT59T7S | UNII = 4B9XT59T7S
| ChEMBL_Ref = {{ebicite|changed|EBI}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00413
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 10110
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 129 | ChEMBL = 129
| PDB_ligand = AZZ
| InChI = 1/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1

| InChIKey = HBOMLICNUCNMMY-XLPZGREQBQ
<!--Chemical data-->
| IUPAC_name = 3'-deoxy-3'-azido-thymidine <br /> 1--5-methylpyrimidine-2,4-dione<ref>{{cite web |url=https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=35370 |title=Zidovudine |work=PubChem Public Chemical Database |publisher=NCBI |access-date=April 10, 2011 |url-status=live |archive-url=https://web.archive.org/web/20121025081252/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=35370 |archive-date=October 25, 2012 }}</ref>
| C=10 | H=13 | N=5 | O=4
| SMILES = O=C1NC(C(C)=CN12O(CO)(N==)C2)=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1 | StdInChI = 1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HBOMLICNUCNMMY-XLPZGREQSA-N | StdInChIKey = HBOMLICNUCNMMY-XLPZGREQSA-N
| CAS_number = 30516-87-1
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 32555
| ATC_prefix = J05
| ATC_suffix = AF01
| PubChem = 35370
| DrugBank = DB00495
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00413
| C = 10 | H = 13 | N = 5 | O = 4
| molecular_weight = 267.242 g/mol
| smiles = O=C/1NC(=O)N(\C=C\1C)2O((\N==)C2)CO
| bioavailability = near complete absoprtion, following first-pass metabolism systemic availability 65% (range 52 to 75%)
| protein_bound =30 to 38%
| metabolism = ]
| elimination_half-life = 0.5 to 3 hours
| excretion = ]
| pregnancy_US = C
| pregnancy_AU = B3
| legal_status = Rx-only
| routes_of_administration = Oral
}} }}


<!-- Definition and uses -->
'''Zidovudine''' (]) or '''azidothymidine''' ('''AZT''') (also called ZDV) is a ] (NRTI), a type of ] used for the treatment of ]/]. It is an ] of ].
'''Zidovudine''' ('''ZDV'''), also known as '''azidothymidine''' ('''AZT'''), was the first ] used to prevent and treat ]. It is generally recommended for use in combination with other antiretrovirals.<ref name=AHFS2016/> It may be used to prevent ] or after a ] or other potential exposure.<ref name=AHFS2016/> It is sold both by itself and together as ] and ].<ref name=AHFS2016/> It can be used by mouth or by slow ].<ref name=AHFS2016>{{cite web|title=Zidovudine|url=https://www.drugs.com/monograph/zidovudine.html|publisher=The American Society of Health-System Pharmacists|access-date=November 28, 2016|url-status=live|archive-url=https://web.archive.org/web/20161221005642/https://www.drugs.com/monograph/zidovudine.html|archive-date=December 21, 2016}}</ref>


<!-- Side effects and mechanism -->
AZT was the first approved treatment for HIV, sold under the names '''Retrovir''' and '''Retrovis'''. AZT use was a major breakthrough in AIDS therapy in the 1990s that significantly altered the course of the illness and helped destroy the notion that HIV/AIDS was a death sentence. AZT slows HIV spread significantly, but does not stop it entirely. This allows HIV to become AZT-resistant over time, and for this reason AZT is usually used in conjunction with other NRTIs and anti-viral drugs. In this form, AZT is used as an ingredient in ] and ], among others. Zidovudine is included in the ]'s "]", which is a list of minimum medical needs for a basic health care system.<ref name="essentialWHO">{{cite web
Common side effects include headaches, fever, and nausea.<ref name=AHFS2016/> Serious side effects include ], ], and ].<ref name=AHFS2016/> It is commonly used in ] and appears to be safe for the fetus.<ref name=AHFS2016/> ZDV is of the ] (NRTI) class.<ref name=AHFS2016/> It works by inhibiting the ] ] that HIV uses to make DNA and therefore decreases replication of the virus.<ref name=AHFS2016/>
| year = March 2005
| url = http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf
| title = WHO Model List of Essential Medicines
| format = PDF
| publisher = World Health Organization
| accessdate = 2006-03-12
}}</ref>


==History== <!-- History and culture -->
Zidovudine was first described in 1964.<ref>{{cite book| vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=505|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA505|url-status=live|archive-url=https://web.archive.org/web/20170908213935/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA505|archive-date=September 8, 2017}}</ref> It was resynthesized from a public-domain formula by ].<ref name="latimes.com"></ref> It was approved in the United States in 1987 and was the first treatment for HIV.<ref name=AHFS2016/><ref>{{cite book | vauthors = Reeves JD, Derdeyn CA |title=Entry Inhibitors in HIV Therapy |date=2007 |publisher=Springer Science & Business Media |isbn=9783764377830 |page=179 |url=https://books.google.com/books?id=zNCJmuWgHAoC&pg=PA179 }}</ref> It is on the ].<ref name="WHO23rd">{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref> It is available as a ].<ref name=AHFS2016/>
===Development===

In the 1950s the theory that most ]s were caused by environmental ]es gained currency. It had long been known that most avian cancers were caused by retroviruses, but this knowledge was of limited use in clinical settings due to a lack of drugs that were effective against them. The development of the first anti-retroviral drugs in the 1950s and 60s led to increasing efforts to isolate the expected human analogs of these avian viruses, and then develop suitable drugs to kill them and produce a universal cure for cancer. These efforts eventually culminated in the "]" in the 1970s.
==Medical uses==

===HIV treatment===
AZT was usually dosed twice a day in combination with other antiretroviral therapies. This approach is referred to as Highly Active Antiretroviral Therapy (]) and is used to prevent the likelihood of HIV resistance.<ref>{{cite journal | vauthors = De Clercq E | title = HIV resistance to reverse transcriptase inhibitors | journal = Biochemical Pharmacology | volume = 47 | issue = 2 | pages = 155–169 | date = January 1994 | pmid = 7508227 | doi = 10.1016/0006-2952(94)90001-9 }}</ref><ref>{{cite journal | vauthors = Yarchoan R, Mitsuya H, Broder S | title = AIDS therapies | journal = Scientific American | volume = 259 | issue = 4 | pages = 110–119 | date = October 1988 | pmid = 3072667 | doi = 10.1038/scientificamerican1088-110 | bibcode = 1988SciAm.259d.110Y }}</ref> As of 2019, the standard is a three-drug once-daily oral treatment that can include AZT.<ref>{{cite journal | vauthors = Phanuphak N, Gulick RM | title = HIV treatment and prevention 2019: current standards of care | journal = Current Opinion in HIV and AIDS | volume = 15 | issue = 1 | pages = 4–12 | date = January 2020 | pmid = 31658110 | doi = 10.1097/COH.0000000000000588 | s2cid = 204952772}}</ref>

===HIV prevention===
AZT has been used for ] (PEP) in combination with another antiretroviral drug called ]. Together they work to substantially reduce the risk of HIV infection following the first single exposure to the virus.<ref>{{cite journal |vauthors=Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS |title=Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis |journal=MMWR Recomm Rep |volume=54 |issue=RR-9 |pages=1–17 |date=September 2005 |pmid=16195697 |url=https://www.cdc.gov/mmwr/PDF/rr/rr5409.pdf}}</ref> More recently, AZT has been replaced by other antiretrovirals such as ] to provide PEP.<ref>{{cite web | url = http://www.bhiva.org/PEPSE.aspx | title = UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011) | access-date = April 7, 2014 | url-status = live | archive-url = https://web.archive.org/web/20140408214056/http://www.bhiva.org/PEPSE.aspx | archive-date = April 8, 2014}}</ref>
Before tenofovir, a principal part of the ] for both pre-exposure prophylaxis and post-exposure treatment of ] of HIV during pregnancy, labor, and delivery and has been proven to be integral to uninfected siblings' ] and ] development.<ref>{{cite web | url = http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf | title = Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health | date = November 17, 2005 | access-date = March 29, 2006 | url-status = dead | archive-url = https://web.archive.org/web/20060422113223/http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf | archive-date = April 22, 2006 | work = AIDSinfo | publisher = U.S. Department of Health and Human Services }}</ref><ref name="pmid17476315">{{cite journal | vauthors = Briand N, Lallemant M, Jourdain G, Techapalokul S, Tunthanathip P, Suphanich S, Chanpoo T, Traisathit P, McIntosh K, Le Coeur S | display-authors = 6 | title = Haematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trial | journal = PLOS Clinical Trials | volume = 2 | issue = 4 | pages = e11 | date = April 2007 | pmid = 17476315 | pmc = 1863515 | doi = 10.1371/journal.pctr.0020011 | doi-access = free }}</ref> Without AZT, 10–15% of fetuses with HIV-infected mothers will themselves become infected.<ref>Science Codex.</ref> AZT has been shown to reduce this risk to 8% when given in a three-part regimen post-conception, delivery, and six weeks post-delivery. Consistent and proactive precautionary measures, such as the rigorous use of antiretroviral medications, ], face masks, heavy-duty rubber gloves, clinically segregated disposable diapers, and avoidance of mouth contact will further reduce child-attendant transmission of HIV to as little as 1–2%.<ref>CIDRZ. Prevention of AIDS Transmission (PMTCT). {{cite web |url=http://www.cidrz.org/pmtct |title=Prevention of mother-to-child HIV transmission (PMTCT) &#124; CIDRZ |access-date=March 31, 2012 |url-status=dead |archive-url=https://web.archive.org/web/20120214203337/http://www.cidrz.org/pmtct |archive-date=February 14, 2012 }}</ref><ref>Transmission of HIV from infants {{cite web |url=http://aidsperspective.net/blog/?p=868 |title=Transmission of HIV from infants to women who breastfeed them. | work = Aids Perspective | date = July 1, 2012 |access-date=August 3, 2012 |url-status=dead |archive-url=https://web.archive.org/web/20131203030636/http://aidsperspective.net/blog/?p=868 |archive-date=December 3, 2013 }}</ref><ref>{{cite journal |vauthors=Connor E, Sperling R, Gelber R, Kiselev P, Scott G, O'Sullivan M, VanDyke R, Bey M, Shearer W, Jacobson R | title=Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group | journal=N Engl J Med | volume=331 | issue=18 | pages=1173–80 | year=1994 | pmid=7935654 | doi=10.1056/NEJM199411033311801| s2cid=13457499 | doi-access=free }}</ref>

During 1994 to 1999, AZT was the primary form of prevention of mother-to-child HIV transmission. AZT prophylaxis prevented more than 1000 parental and infant deaths from AIDS in the United States.<ref name="pmid16741877">{{cite journal | vauthors = Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA | display-authors = 6 | title = The survival benefits of AIDS treatment in the United States | journal = The Journal of Infectious Diseases | volume = 194 | issue = 1 | pages = 11–19 | date = July 2006 | pmid = 16741877 | doi = 10.1086/505147 | doi-access = free }}</ref> In the U.S. at that time, the accepted standard of care for HIV-positive mothers was known as the 076 regimen and involved five daily doses of AZT from the second trimester onwards, as well as AZT intravenously administered during labour.<ref>{{cite journal | vauthors = Morris K | title = Short course of AZT halves HIV-1 perinatal transmission | journal = Lancet | volume = 351 | issue = 9103 | pages = 651 | date = February 1998 | pmid = 9500334 | doi = 10.1016/S0140-6736(05)78436-1 | s2cid = 8293828 }}</ref> As this treatment was lengthy and expensive, it was deemed unfeasible in the ], where mother-to-child transmission was a significant problem. A number of studies were initiated in the late 1990s that sought to test the efficacy of a shorter, simpler regimen for use in 'resource-poor' countries.<ref name="Crane, Johanna 2010">{{cite journal | vauthors = Crane J | title = Adverse events and placebo effects: African scientists, HIV, and ethics in the 'global health sciences' | journal = Social Studies of Science | volume = 40 | issue = 6 | pages = 843–870 | date = December 2010 | pmid = 21553555 | doi = 10.1177/0306312710371145 | s2cid = 26027925 }}</ref> This AZT short course was an inferior standard of care and would have been considered malpractice if trialed in the US; however, it was nonetheless a treatment that would improve the care and survival of impoverished subjects.<ref name="Crane, Johanna 2010"/>

=== Antibacterial properties ===
Zidovudine also has antibacterial properties,<ref>{{cite journal | vauthors = DeSarno AE, Parcell BJ, Coote PJ | title = Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains of Klebsiella pneumoniae | journal = Pathogens and Disease | volume = 78 | issue = 9 | pages = ftaa063 | date = December 2020 | pmid = 33053176 | doi = 10.1093/femspd/ftaa063 | doi-access = free | hdl = 10023/24137 | hdl-access = free }}</ref> though not routinely used in clinical settings. It acts on bacteria with a mechanism of action still not fully explained. Promising results from '']'' and '']'' studies showed the efficacy of AZT also against multidrug-resistant ] (including ] carrying and metallo-] producing isolates), especially in combination with other active agents (e.g. ], ], ]).<ref>{{cite journal | vauthors = Zhou YF, Liu P, Dai SH, Sun J, Liu YH, Liao XP | title = Activity of Tigecycline or Colistin in Combination with Zidovudine against Escherichia coli Harboring ''tet''(X) and ''mcr-1'' | journal = Antimicrobial Agents and Chemotherapy | volume = 65 | issue = 1 | date = December 2020 | pmid = 33020156 | pmc = 7927862 | doi = 10.1128/AAC.01172-20 }}</ref><ref>{{cite journal | vauthors = Antonello RM, Di Bella S, Betts J, La Ragione R, Bressan R, Principe L, Morabito S, Gigliucci F, Tozzoli R, Busetti M, Knezevich A, Furlanis L, Fontana F, Luzzaro F, Luzzati R, Lagatolla C | display-authors = 6 | title = Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales | journal = International Journal of Antimicrobial Agents | volume = 58 | issue = 1 | pages = 106362 | date = July 2021 | pmid = 34010710 | doi = 10.1016/j.ijantimicag.2021.106362 | s2cid = 234791392 }}</ref>

==Side effects==
Most common side effects include nausea, vomiting, ] (heartburn), headache, cosmetic reduction in abdominal body fat, trouble sleeping, and loss of appetite. Less common side effects include faint discoloration of fingernails and toenails, mood elevation, occasional tingling or transient numbness of the hands or feet, and minor skin discoloration. Allergic reactions are rare.<ref>{{cite web|url=http://www.medicinenet.com/zidovudine_azt-oral/page2.htm|title=zidovudine, Retrovir|date=August 12, 2010|publisher=Medicinenet.com|access-date=December 14, 2010|url-status=live|archive-url=https://web.archive.org/web/20101220035237/http://www.medicinenet.com/zidovudine_azt-oral/page2.htm|archive-date=December 20, 2010}}</ref>

Early long-term higher-dose therapy with AZT was initially associated with side effects that sometimes limited therapy, including ], ], ], ], and ]. All of these conditions were generally found to be reversible upon reduction of AZT dosages. They have been attributed to several possible causes, including transient depletion of ], sensitivity of the γ-DNA polymerase in some cell ],<ref>{{cite journal | vauthors = Sun R, Eriksson S, Wang L | title = Identification and characterization of mitochondrial factors modulating thymidine kinase 2 activity | journal = Nucleosides, Nucleotides & Nucleic Acids | volume = 29 | issue = 4–6 | pages = 382–385 | date = June 2010 | pmid = 20544523 | doi = 10.1080/15257771003741018 | s2cid = 13539181 }}</ref> the depletion of ], ], reduction of intracellular <small>L</small>-] or ] of the muscle cells.<ref name="Scruggs">{{cite journal | vauthors = Scruggs ER, Dirks Naylor AJ | title = Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy | journal = Pharmacology | volume = 82 | issue = 2 | pages = 83–88 | year = 2008 | pmid = 18504416 | doi = 10.1159/000134943 | s2cid = 2044833 | doi-access = free }}</ref> Anemia due to AZT was successfully treated using ] to stimulate ] production.<ref>{{cite journal | vauthors = Fisher JW | title = Erythropoietin: physiologic and pharmacologic aspects | journal = Proceedings of the Society for Experimental Biology and Medicine | volume = 216 | issue = 3 | pages = 358–369 | date = December 1997 | pmid = 9402140 | doi = 10.3181/00379727-216-44183 | s2cid = 26177904 }}</ref><ref>{{cite journal | vauthors = Fisher JW | title = Erythropoietin: physiology and pharmacology update | journal = Experimental Biology and Medicine | volume = 228 | issue = 1 | pages = 1–14 | date = January 2003 | pmid = 12524467 | doi = 10.1177/153537020322800101 | s2cid = 2829677 }}</ref> Drugs that inhibit ] ], such as ], ], ] (aspirin) and ] decreased the elimination rate and increased the therapeutic strength of the medication.<ref>{{cite web | url=http://www.medicinenet.com/zidovudine_azt-oral/article.htm | title=ZIDOVUDINE (AZT) – ORAL (Retrovir) side effects, medical uses, and drug interactions | access-date=January 9, 2006 | publisher=MedicineNet | url-status=live | archive-url=https://web.archive.org/web/20050630080343/http://www.medicinenet.com/zidovudine_azt-oral/article.htm | archive-date=June 30, 2005 }}</ref> Today, side effects are much less common with the use of lower doses of AZT.<ref>Side Effects. NAM Aidsmap. {{cite web |url=http://www.aidsmap.com/Side-effects/page/1730907/ |title=Zidovudine (AZT, ''Retrovir'') |access-date=March 28, 2012 |url-status=live |archive-url=https://web.archive.org/web/20111226015716/http://www.aidsmap.com/Side-effects/page/1730907/ |archive-date=December 26, 2011 }}</ref>
According to IARC, there is sufficient evidence in experimental animals for the ]icity of zidovudine; it is possibly carcinogenic to humans (]).<ref>{{cite web|url=http://www.inchem.org/documents/iarc/vol76/zidovudine.html|title=Summary of Data Reported and Evaluation|year=2000|access-date=August 11, 2012|url-status=live|archive-url=https://web.archive.org/web/20120104162609/http://inchem.org/documents/iarc/vol76/zidovudine.html|archive-date=January 4, 2012}}</ref> In 2009, the State of California added zidovudine to its list of chemicals "known to the state of California to cause cancer and other reproductive harm."<ref>{{cite web |title=State of California Environmental Protection Agency Office of Environmental Hazard Assessment Safe Drinking Water and Toxic Enforcement Act of 1986 Chemicals Known to the State to Cause Cancer or Reproductive Toxicity July 29, 1011 |url=https://tig.org.za/AZT_OEHHA_listing/6.AZT_listed_as_a_chemical_known_to_the_state_of_California_to_cause_cancer_or_reproductive_toxicity_18_December_2009.pdf|access-date=November 14, 2022|date=July 29, 2011}}</ref>

===Viral resistance===
Even at the highest doses that can be tolerated in patients, AZT is not potent enough to prevent all HIV replication and may only slow the replication of the virus and progression of the disease. Prolonged AZT treatment can lead to HIV developing resistance to AZT by ] of its ].<ref>{{cite journal | vauthors = Richman DD | title = Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus | journal = The American Journal of Medicine | volume = 88 | issue = 5B | pages = 8S–10S | date = May 1990 | pmid = 2186629 | doi = 10.1016/0002-9343(90)90414-9 }}</ref><ref>{{cite journal | vauthors = Wainberg MA, Brenner BG, Turner D | title = Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase | journal = Antimicrobial Agents and Chemotherapy | volume = 49 | issue = 5 | pages = 1671–1678 | date = May 2005 | pmid = 15855480 | pmc = 1087622 | doi = 10.1128/AAC.49.5.1671-1678.2005 }}</ref> To slow the development of resistance, physicians generally recommend that AZT be given in combination with another ] and an antiretroviral from another group, such as a ], ], or ]; this type of therapy is known as ] (Highly Active Anti Retroviral Therapy).

==Mechanism of action==
]
AZT is a ] analogue. AZT works by selectively inhibiting HIV's ], the ] that the virus uses to make a ] copy of its ]. Reverse transcription is necessary for production of HIV's double-stranded DNA, which would be subsequently integrated into the genetic material of the infected ] (where it is called a ]).<ref name=MitsuyaPNAS/><ref name="Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D, Gelmann E, Lehrman S, Blum R, Barry D 1986 575–80"/><ref>{{cite journal |vauthors=Mitsuya H, Yarchoan R, Broder S | title=Molecular targets for AIDS therapy | journal=Science | volume=249 | issue=4976 | pages=1533–44 | year=1990 | pmid=1699273 | doi=10.1126/science.1699273|bibcode = 1990Sci...249.1533M | url=https://zenodo.org/record/1230944 | type=Submitted manuscript }}</ref>


Cellular enzymes convert AZT into the effective 5'-triphosphate form. Studies have shown that the termination of HIV's forming DNA chains is the specific factor in the inhibitory effect.<ref>{{cite journal | vauthors = Quan Y, Rong L, Liang C, Wainberg MA | title = Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1 | journal = Journal of Virology | volume = 73 | issue = 8 | pages = 6700–6707 | date = August 1999 | pmid = 10400767 | pmc = 112754 | doi = 10.1128/JVI.73.8.6700-6707.1999 }}</ref>
] of the Barbara Ann Karmanos Cancer Institute and ] first synthesized AZT in 1964 under a ] ] (NIH) ].<ref name=pmid20018391>{{Cite pmid|20018391}}</ref><ref name=horwitz64>{{cite journal | title = The monomesylates of 1-(2-deoxy-bd-lyxofuranosyl) thymines
| last = Horwitz | first = JP | coauthors = Chua J; Noel MJ | journal = Org. Chem. Ser. Monogr | year = 1964 | volume = 29 | pages = 2076–9 |doi=10.1021/jo01030a546 |accessdate = 2010-07-02 | issue = 7}}</ref><ref name=filmazt2002>{{Cite video | people = Detours V; Henry D (writers/directors) | title = I am alive today (history of an AIDS drug) | medium = Film | publisher = ADR Productions/Good & Bad News | location = | date = 2002 }}</ref> Development was shelved after it proved insufficiently effective against tumors in mice.<ref name=pmid20018391/><ref name="nytimes">{{cite news | url = http://query.nytimes.com/gst/fullpage.html?sec=health&res=9A0DE4D81F3CF933A1575AC0A960948260 | title = A Failure Led to Drug Against AIDS | work = ] | date = 1986-09-20 | accessdate = 2010-06-30 }}</ref> In 1974, Wolfram Ostertag of the ] in ] reported that AZT was active against Friend murine leukaemia virus, a ], in a mouse culture system.<ref>{{cite pmid | 4531031 }}</ref>


At very high doses, AZT's triphosphate form may also inhibit ] used by human cells to undergo ], but regardless of dosage AZT has an approximately 100-fold greater affinity for HIV's reverse transcriptase.<ref name=FurmanPNAS>{{cite journal | vauthors = Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H | display-authors = 6 | title = Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 83 | issue = 21 | pages = 8333–8337 | date = November 1986 | pmid = 2430286 | pmc = 386922 | doi = 10.1073/pnas.83.21.8333 | doi-access = free | bibcode = 1986PNAS...83.8333F }}</ref> The selectivity has been suggested to be due to the cell's ability to quickly repair its own DNA chain if it is disrupted by AZT during its formation, whereas the HIV virus lacks that ability.<ref>Induction of Endogenous Virus and of Thymidline Kinase. {{cite web |url=http://www.pnas.org/content/71/12/4980.full.pdf |title=Induction of Endogenous Virus and of Thymidline Kinase by Bromodeoxyuridine in Cell Cultures Transformed by Friend Virus|access-date=November 14, 2022 |url-status=live |archive-url=https://web.archive.org/web/20150924164155/http://www.pnas.org/content/71/12/4980.full.pdf |archive-date=September 24, 2015 }}</ref> Thus AZT inhibits HIV replication without affecting the function of uninfected cells.<ref name=MitsuyaPNAS/> At sufficiently high dosages, AZT begins to inhibit the cellular DNA polymerase used by ] to replicate, accounting for its potentially toxic but reversible effects on ] and ]s, causing ].<ref name="Yarchoan R, Mitsuya H, Myers C, Broder S 1989 726–38"/><ref>{{cite journal | vauthors = Collins ML, Sondel N, Cesar D, Hellerstein MK | title = Effect of nucleoside reverse transcriptase inhibitors on mitochondrial DNA synthesis in rats and humans | journal = Journal of Acquired Immune Deficiency Syndromes | volume = 37 | issue = 1 | pages = 1132–1139 | date = September 2004 | pmid = 15319672 | doi = 10.1097/01.qai.0000131585.77530.64 | s2cid = 20020419 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Parker WB, White EL, Shaddix SC, Ross LJ, Buckheit RW, Germany JM, Secrist JA, Vince R, Shannon WM | display-authors = 6 | title = Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5'-triphosphates of carbovir, 3'-azido-3'-deoxythymidine, 2',3'-dideoxyguanosine and 3'-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs | journal = The Journal of Biological Chemistry | volume = 266 | issue = 3 | pages = 1754–1762 | date = January 1991 | pmid = 1703154 | doi = 10.1016/S0021-9258(18)52360-7 | doi-access = free }}</ref><ref>{{cite book | vauthors = Rang HP, Dale MM, Ritter JM | title=Pharmacology | edition=3rd | publisher=Pearson Professional Ltd | year=1995 | isbn=978-0-443-05974-2}}</ref><ref>{{cite journal | vauthors = Balzarini J, Naesens L, Aquaro S, Knispel T, Perno C, De Clercq E, Meier C | title = Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine) | journal = Molecular Pharmacology | volume = 56 | issue = 6 | pages = 1354–1361 | date = December 1999 | pmid = 10570065 | doi = 10.1124/mol.56.6.1354 | url = http://molpharm.aspetjournals.org/cgi/content/full/56/6/1354 | url-status = live | s2cid = 25678740 | archive-url = https://web.archive.org/web/20070921090344/http://molpharm.aspetjournals.org/cgi/content/full/56/6/1354 | archive-date = September 21, 2007 }}</ref>
The anti-retroviral approach to develop a "silver bullet" cancer cure ultimately failed. Contrary to early belief, today it is estimated that viruses account for only 10 to 20% of human cancers. However, these efforts advanced the knowledge of cancer considerably, and led to rapid development of many anti-retroviral drugs, which would later prove useful. Zidovudine (AZT) was approved for marketing by the U.S. ] (FDA) on March 20, 1987.<ref name="Cimons">{{cite news | last = Cimons | first = Marlene | title = U.S. Approves Sale of AZT to AIDS Patients | work = Los Angeles Times | pages = 1 | date = 21 March 1987 }}</ref>


==Chemistry== ==Chemistry==
] ]


AZT crystallizes in a ] structure, forming a ]ed network of base-paired ]s; its crystal structure was reported in 1988.<ref>{{cite journal |author=Dyer I, Low JN, Tollin P, Wilson HR, Howie RA |title=Structure of 3'-azido-3'-deoxythymidine, AZT |journal=Acta Crystallogr C |volume=44 ( Pt 4) |issue= |pages=767–9 |year=1988 |month=April |pmid=3271074 |doi= |url=}}</ref> Enantiopure AZT crystallizes in the ] space group P2<sub>1</sub>. The primary intermolecular bonding motif is a hydrogen bonded dimeric ring formed from two N-H<sup>...</sup>O interactions.<ref>{{cite journal |vauthors=Dyer I, Low JN, Tollin P, Wilson HR, Howie RA |title=Structure of 3'-azido-3'-deoxythymidine, AZT |journal=Acta Crystallogr C |volume=44 |issue= 4|pages=767–9 |date=April 1988 |pmid=3271074 |doi= 10.1107/S0108270188000368|bibcode=1988AcCrC..44..767D }}</ref><ref>{{cite journal |journal= Proc Natl Acad Sci USA |year= 1987 |volume= 84 |issue= 23 |pages= 8239–8242 |title= Azidothymidine: crystal structure and possible functional role of the azido group |vauthors= Camerman A, Mastropaolo D, Camerman N |pmid= 2446321 |doi=10.1073/pnas.84.23.8239 |pmc=299517|bibcode= 1987PNAS...84.8239C |doi-access= free }}</ref>


==HIV Treatment== ==History==
In 1984, shortly after the ] (HIV) had been confirmed as the cause of AIDS, scientists at the ] (now GlaxoSmithKline) began searching for compounds to treat the disease. Burroughs-Wellcome had expertise in viral diseases, led by researchers including Gertrude Elion, David Barry, Paul (Chip) McGuirt Jr., Philip Furman, Martha St. Clair, Janet Rideout, Sandra Lehrman and others. Their research efforts focused on the viral enzyme ]. Reverse transcriptase is an enzyme that retroviruses, including HIV, utilize to replicate themselves. Scientists at Burroughs-Wellcome began to identify and synthesize compounds and developed a screen to test for activity against murine (mouse) retroviruses. One compound, coded "BW A509U", was tested and demonstrated potent activity against mouse viruses.


===Initial cancer research===
At the same time, ], ], and ] of the United States ] (NCI) had initiated an independent program to develop therapies for HIV/AIDS. The Burroughs-Wellcome scientists were not working directly with HIV, so the two groups began a collaboration. In February 1985, the NCI scientists showed that BW A509U, one of 11 compounds sent to them by Burroughs-Wellcome, had potent activity against HIV in the test tube. Several months later, Broder, Mitsuya, and Yarchoan started the initial phase 1 ] of AZT at the NCI, in collaboration with scientists from Burroughs-Wellcome and ].<ref name=pmid20018391/><ref name=MitsuyaPNAS>{{cite journal | author=Mitsuya H, Weinhold K, Furman P, St Clair M, Lehrman S, Gallo R, Bolognesi D, Barry D, Broder S | title=3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus ''in vitro'' | journal=Proc Natl Acad Sci USA | volume=82 | issue=20 | pages=7096–100 | year=1985 | pmid=2413459 | doi=10.1073/pnas.82.20.7096 | pmc=391317}}</ref><ref name="Yarchoan R, Mitsuya H, Myers C, Broder S 1989 726–38">{{cite journal | doi=10.1056/NEJM198909143211106 | author=Yarchoan R, Mitsuya H, Myers C, Broder S | title=Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides | journal=N Engl J Med | volume=321 | issue=11 | pages=726–38 | year=1989 | pmid=2671731}}</ref><ref name="Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D, Gelmann E, Lehrman S, Blum R, Barry D 1986 575–80">{{cite journal | author=Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D, Gelmann E, Lehrman S, Blum R, Barry D | title=Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex | journal=Lancet | volume=1 | issue=8481 | pages=575–80 | year=1986 | pmid=2869302 | doi=10.1016/S0140-6736(86)92808-4}}</ref> This trial suggested that the drug could be safely administered to patients with HIV and that it could increase ] counts in HIV-infected patients.


In the 1960s, the theory that most ]s were caused by environmental ]es gained clinical support and funding. It had recently become known, due to the work of Nobel laureates ] and ],<ref name="test75">{{cite web|url=https://www.nobelprize.org/prizes/medicine/1975/temin/lecture/|archiveurl=https://web.archive.org/web/20170103002308/http://www.nobelprize.org/nobel_prizes/medicine/laureates/1975/temin-lecture.html|url-status=dead|title=The Nobel Prize in Physiology or Medicine 1975|archivedate=January 3, 2017|website=NobelPrize.org}}</ref> that nearly all avian cancers were caused by bird retroviruses, but corresponding human retroviruses had not yet been found.
A ]-controlled ] of AZT was subsequently conducted by Burroughs-Wellcome. The study found that AZT could prolong the life of patients with AIDS.<ref>{{cite journal | author=Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, et al. | title=The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial | journal=N Engl J Med | volume=317 | issue=4 | pages=185–91 | year=1987 | pmid=3299089 | doi=10.1056/NEJM198707233170401}}</ref> Burroughs-Wellcome filed for a patent for AZT in 1985. The United States ] (FDA) approved the drug (via the then-new ]) for use against HIV, AIDS, and ''AIDS Related Complex'' (ARC, a now-defunct medical term for pre-AIDS illness) on March 20, 1987.<ref name="Cimons"/> The time between the first demonstration that AZT was active against HIV in the laboratory and its approval was 25 months, one of the shortest periods of drug development in recent history.


In parallel work, other compounds that successfully blocked the synthesis of nucleic acids had been proven to be both antibacterial, antiviral, and anticancer agents, the leading work being done at the laboratory of Nobel laureates ] and ], leading to the development of the antitumor agent ].<ref name="test88">{{cite web|url=https://www.nobelprize.org/nobel_prizes/medicine/laureates/1988/elion-lecture.pdf|archiveurl=https://web.archive.org/web/20170808212611/http://www.nobelprize.org/nobel_prizes/medicine/laureates/1988/elion-lecture.pdf|url-status=dead|title=The Purine Path To Chemotherapy|archivedate=August 8, 2017}}</ref>
AZT was subsequently approved as a preventive treatment in 1990. It was initially administered in much higher dosages than today, typically 400&nbsp;mg every four hours (even at night). However, the paucity of alternatives for treating AIDS at that time affected the risk/benefit ratio, with the certain mortality of HIV infection outweighing the risk of drug toxicity. One of AZT's side effects is ], a common complaint in early trials.


Richard E. Beltz first synthesized AZT in 1961, but did not publish his research.<ref>{{cite news |last1=Marsa |first1=Linda |title=Toxic Hope: Widely Embraced, the AIDS Drug is now under Heavy Fire |url=https://www.latimes.com/archives/la-xpm-1993-06-20-tm-10183-story.html |work=Los Angeles Times |date=June 20, 1993}}</ref><ref>{{cite web |last1=Brinck |first1=Anthony |title=Inventing AZT |url=http://www.tig.org.za/Inventing_AZT.pdf}}</ref>] of the Barbara Ann Karmanos Cancer Institute and ] synthesized AZT in 1964 under a ] ] (NIH) ].<ref name=pmid20018391>{{cite journal | vauthors = Broder S | title = The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic | journal = Antiviral Research | volume = 85 | issue = 1 | pages = 1–18 | date = January 2010 | pmid = 20018391 | pmc = 2815149 | doi = 10.1016/j.antiviral.2009.10.002 }}</ref><ref name=horwitz64>{{cite journal | title = The monomesylates of 1-(2-deoxy-bd-lyxofuranosyl) thymines| vauthors = Horwitz JP, Chua J, Noel MJ | journal = Org. Chem. Ser. Monogr | year = 1964 | volume = 29 | pages = 2076–9 |doi=10.1021/jo01030a546 | issue = 7}}</ref><ref name=filmazt2002>{{cite video | people = Detours V; Henry D (writers/directors) | title = I am alive today (history of an AIDS drug) | medium = Film | publisher = ADR Productions/Good & Bad News | date = 2002 }}</ref> Development was shelved after it proved biologically inert in mice.<ref name=pmid20018391/><ref name="nytimes">{{cite news | url = https://www.nytimes.com/1986/09/20/us/a-failure-led-to-drug-against-aids.html | title = A Failure Led to Drug Against AIDS | work = ] | date = September 20, 1986 | access-date = June 30, 2010 | url-status = live | archive-url = https://web.archive.org/web/20090816081427/http://query.nytimes.com/gst/fullpage.html?sec=health | archive-date = August 16, 2009 }}</ref> In 1974, Wolfram Ostertag of the ] in ], Germany, reported that AZT specifically targeted ] (strain of ]).<ref>{{cite journal | vauthors = Ostertag W, Roesler G, Krieg CJ, Kind J, Cole T, Crozier T, Gaedicke G, Steinheider G, Kluge N, Dube S | display-authors = 6 | title = Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 71 | issue = 12 | pages = 4980–4985 | date = December 1974 | pmid = 4531031 | pmc = 434023 | doi = 10.1073/pnas.71.12.4980 | doi-access = free | bibcode = 1974PNAS...71.4980O }}</ref>
Current treatment regimens involve lower dosages (e.g., 300&nbsp;mg) of AZT taken twice a day, almost always as part of '']'' (HAART) protocols. AZT is combined with other drugs in order to prevent mutation of HIV into an AZT-resistant form.<!--
--><ref>{{cite journal | author=De Clercq E | title=HIV resistance to reverse transcriptase inhibitors | journal=Biochem Pharmacol | volume=47 | issue=2 | pages=155–69 | year=1994 | pmid=7508227 | doi=10.1016/0006-2952(94)90001-9}}</ref><!--
--><ref>{{cite journal | author=Yarchoan R, Mitsuya H, Broder S | title=AIDS therapies | journal=Sci Am | volume=259 | issue=4 | pages=110–9 | year=1988 | pmid=3072667 | doi=10.1038/scientificamerican1088-110}}</ref>


This report attracted little interest from other researchers as the Friend leukemia virus is a retrovirus, and at the time, there were no known human diseases caused by retroviruses.<ref name="Sneader 2006 260–261">{{cite book | vauthors = Sneader W |title=Drug Discovery – A History |url=https://archive.org/details/drugdiscoveryhis00snea |url-access=limited |publisher=Wiley |year=2006 |pages=–261 |isbn=978-0-471-89980-8 }}</ref>
==HIV Prophylaxis==
AZT may be used as ] in combination with other antiretroviral medications, substantially reducing the risk of HIV infection following a significant exposure to the virus (such as a needle-stick injury involving blood or body fluids from an individual known to be infected with HIV).<!--
--><ref>{{cite web | url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm | title = Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV | accessdate = 2006-03-29}}</ref>


===HIV/AIDS research===
AZT is also recommended as part of a regimen to prevent ] of HIV during pregnancy, labor, and delivery.<!--
--><ref>{{cite web | url = http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf | title = Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health | accessdate = 2006-03-29}}</ref>
With no treatment, approximately 25% of infants whose mothers are infected with HIV will become infected. AZT has been shown to reduce this risk to approximately 8% when given in a three-part regimen during pregnancy, delivery and to the infant for 6 weeks after birth.<!--
--><ref>{{cite journal | author=Connor E, Sperling R, Gelber R, Kiselev P, Scott G, O'Sullivan M, VanDyke R, Bey M, Shearer W, Jacobson R | title=Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group | journal=N Engl J Med | volume=331 | issue=18 | pages=1173–80 | year=1994 | pmid=7935654 | doi=10.1056/NEJM199411033311801}}</ref>
During the period from 1994 to 1999 when this was the primary form of prevention of mother-to-child HIV transmission, AZT prophylaxis prevented more than 1000 infant HIV infections.<!--
--><ref name="pmid16741877">{{cite journal |author=Walensky RP, Paltiel AD, Losina E, ''et al.'' |title=The survival benefits of AIDS treatment in the United States |journal=J. Infect. Dis. |volume=194 |issue=1 |pages=11–9 |year=2006 |month=July |pmid=16741877 |doi=10.1086/505147 |url=}}</ref>
Use of appropriate combinations of antiretroviral medications, ] and avoidance of breast feeding can further reduce mother-child transmission of HIV to 1–2%.


In 1983, researchers at the Institut Pasteur in Paris identified the retrovirus now known as the Human Immunodeficiency Virus (HIV) as the cause of acquired immunodeficiency syndrome (AIDS) in humans.<ref>{{cite journal | vauthors = Weiss RA | title = How does HIV cause AIDS? | journal = Science | volume = 260 | issue = 5112 | pages = 1273–1279 | date = May 1993 | pmid = 8493571 | doi = 10.1126/science.8493571 | bibcode = 1993Sci...260.1273W }}</ref><ref>{{cite journal | vauthors = Douek DC, Roederer M, Koup RA | title = Emerging concepts in the immunopathogenesis of AIDS | journal = Annual Review of Medicine | volume = 60 | pages = 471–484 | year = 2009 | pmid = 18947296 | pmc = 2716400 | doi = 10.1146/annurev.med.60.041807.123549 }}</ref> Shortly thereafter, ], ], and ] of the United States ] (NCI) initiated a program to develop therapies for HIV/AIDS.<ref>NIH Clinical Center's 50th Anniversary. {{cite web |url=http://www.cc.nih.gov/about/news/anniver50/_pdf/CC_50th_Anniversary_Celebration.pdf |title=Clinical Center 50th Anniversary Celebration |access-date=April 18, 2012 |url-status=dead |archive-url=https://web.archive.org/web/20130619093432/http://www.cc.nih.gov/about/news/anniver50/_pdf/CC_50th_Anniversary_Celebration.pdf |archive-date=June 19, 2013 }}</ref> Using a line of ] that they had made, they developed an assay to screen drugs for their ability to protect CD4<sup>+</sup> T cells from being killed by HIV. In order to expedite the process of discovering a drug, the NCI researchers actively sought collaborations with pharmaceutical companies having access to libraries of compounds with potential antiviral activity.<ref name=MitsuyaPNAS>{{cite journal | vauthors = Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S | display-authors = 6 | title = 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 82 | issue = 20 | pages = 7096–7100 | date = October 1985 | pmid = 2413459 | pmc = 391317 | doi = 10.1073/pnas.82.20.7096 | doi-access = free | bibcode = 1985PNAS...82.7096M }}</ref> This assay could simultaneously test both the anti-HIV effect of the compounds and their toxicity against infected T cells.
==Side effects==
Chronic, high-dose therapy with AZT is associated with significant side effects, including ], ], ], ], and ]. Damage to muscle cells is reversible upon cessation of AZT treatment. It has been attributed to several possible causes including depletion of ], sensitivity of the γ-DNA polymerase in the cell ],<ref>{{cite pmid | 20544523}}</ref> the depletion of ], ], reduction of intracellular L-] or ] of the muscle cells.<ref name = Scruggs>{{cite pmid | 18504416 }}</ref> Anemia due to AZT can be treated using ] to stimulate ] production.<ref>{{cite pmid|9402140}}</ref><ref>{{cite pmid|12524467 }}</ref> Drugs that inhibit ] ], such as ], ] (Aspirin) and ], decrease the elimination rate and increase the toxicity of the drug.<!--
--><ref>{{cite web | url=http://www.medicinenet.com/zidovudine_azt-oral/article.htm | title=ZIDOVUDINE (AZT) - ORAL (Retrovir) side effects, medical uses, and drug interactions | accessdate=2006-01-09 | publisher=MedicineNet}}</ref> Minor side effects include nausea and vomiting, headache, changes in the distribution of body fat, sleep disruption and ] while less common but potentially serious side effects include discoloration of fingernails and toenails, mood changes, tingling or numbness of the hands or feet, easy bruising or bleeding and seizures. Serious allergic reactions are rare.<ref>{{cite web | url = http://www.medicinenet.com/zidovudine_azt-oral/page2.htm | title = zidovudine, Retrovir | publisher = Medicinenet.com | accessdate = 2010-12-14 | date = 2010-08-12 }}</ref>


In June 1984, Burroughs-Wellcome virologist Marty St. Clair set up a program to discover drugs with the potential to inhibit HIV replication. Burroughs-Wellcome had expertise in nucleoside analogs and viral diseases, led by researchers including ], ], David Barry, Paul (Chip) McGuirt Jr., Philip Furman, Martha St. Clair, ], Sandra Lehrman and others. Their research efforts were focused in part on the viral enzyme ]. Reverse transcriptase is an enzyme that retroviruses, including HIV, utilize to replicate themselves. Secondary testing was performed in mouse cells infected with the retroviruses Friend virus or Harvey sarcoma virus, as the Wellcome group did not have a viable in-house HIV antiviral assay in place at that time, and these other retroviruses were believed to represent reasonable surrogates. AZT proved to be a remarkably potent inhibitor of both Friend virus and Harvey sarcoma virus, and a search of the company's records showed that it had demonstrated low toxicity when tested for its antibacterial activity in rats many years earlier. Based in part on these results, AZT was selected by nucleoside chemist Janet Rideout as one of 11 compounds to send to the NCI for testing in that organization's HIV antiviral assay.<ref name="Sneader 2006 260–261"/>
==Viral resistance==
Even at very high doses, AZT does not destroy the HIV infection, but only delays the replication of the virus and the progression of the disease. During prolonged AZT treatment, HIV has the ability to gain an increased resistance to AZT by ] of its ].<ref>{{cite pmid|2186629}}</ref><ref>{{cite pmid|15855480}}</ref> To slow the development of resistance, physicians generally recommend that AZT be given in combination with another ] and an antiretroviral from another group, such as a ] or a ]; this type of therapy is known as ] (Highly Active Anti Retroviral Therapy). AZT has been shown to work additively or synergistically with many antiviral agents such as ] and ]; however, ] decreases the antiviral effect of AZT .


In February 1985, the NCI scientists found that AZT had potent efficacy in vitro.<ref name=MitsuyaPNAS/><ref name=pmid20018391/>
==Mechanism of action==
Several months later, a phase 1 ] of AZT at the NCI was initiated at the NCI and Duke University.<ref name="Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D, Gelmann E, Lehrman S, Blum R, Barry D 1986 575–80">{{cite journal |vauthors=Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D, Gelmann E, Lehrman S, Blum R, Barry D | title=Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex | journal=Lancet | volume=1 | issue=8481 | pages=575–80 | year=1986 | pmid=2869302 | doi=10.1016/S0140-6736(86)92808-4| s2cid=37985276 }}</ref><ref name="Yarchoan R, Mitsuya H, Myers C, Broder S 1989 726–38">{{cite journal | doi=10.1056/NEJM198909143211106 |vauthors=Yarchoan R, Mitsuya H, Myers C, Broder S | title=Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides | journal=N Engl J Med | volume=321 | issue=11 | pages=726–38 | year=1989 | pmid=2671731}}</ref><ref>{{cite journal |vauthors=Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Lehrman SN, Blum RM, Barry DW |title=Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex |journal=Lancet |volume=1 |issue=8481 |pages=575–80 |year=1986 |pmid=2869302 |doi= 10.1016/s0140-6736(86)92808-4|s2cid=37985276 }}</ref>
]
In doing this Phase I trial, they built on their experience in doing an earlier trial, with suramin, another drug that had shown effective anti-HIV activity in the laboratory. This initial trial of AZT proved that the drug could be safely administered to patients with HIV, that it increased their ] counts, restored T cell immunity as measured by skin testing, and that it showed strong evidence of clinical effectiveness, such as inducing weight gain in AIDS patients. It also showed that levels of AZT that worked in vitro could be injected into patients in serum and suppository form, and that the drug penetrated deeply only into infected brains.
AZT works by inhibiting the action of ], the ] that HIV uses to make a ] copy of its ]. Reverse transcription is necessary for production of the viral double-stranded ], which is subsequently integrated into the genetic material of the infected ] (where it is called a ]).<!--
--><ref>{{cite journal | author=Mitsuya H, Yarchoan R, Broder S | title=Molecular targets for AIDS therapy | journal=Science | volume=249 | issue=4976 | pages=1533–44 | year=1990 | pmid=1699273 | doi=10.1126/science.1699273}}</ref><!--
--><ref name=MitsuyaPNAS/><!--
--><ref name="Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D, Gelmann E, Lehrman S, Blum R, Barry D 1986 575–80"/>


===Patent filed and FDA approval===
The azido group increases the ] nature of AZT, allowing it to cross ]s easily by ] and thereby also to cross the ]. Cellular enzymes convert AZT into the effective 5'-triphosphate form. Studies have shown that the termination of the formed DNA chains is the specific factor in the inhibitory effect.


A flawed ], ]-controlled ] of AZT was subsequently conducted by Burroughs-Wellcome and suggested that AZT safely prolongs the lives of people with HIV. However, it was quickly unblinded and several more in the drug receiving group later perished.<ref>{{cite web | url=https://www.snopes.com/news/2021/09/21/did-azt-kill-more-patients-than-aids/#A%20Fast-Track%20Approval%20Rife%20with%20Controversy | title=Did Controversial AZT Treatment Kill More Patients than AIDS in '80s, '90s? | date=September 21, 2021 }}</ref><ref>{{cite journal | vauthors = Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT | display-authors = 6 | title = The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial | journal = The New England Journal of Medicine | volume = 317 | issue = 4 | pages = 185–191 | date = July 1987 | pmid = 3299089 | doi = 10.1056/NEJM198707233170401 }}</ref> Burroughs-Wellcome filed for a patent for AZT in 1985. The Anti-Infective Advisory Committee to United States ] (FDA) voted ten to one to recommend the approval of AZT.<ref>{{cite journal | vauthors = Brook I | title = Approval of zidovudine (AZT) for acquired immunodeficiency syndrome. A challenge to the medical and pharmaceutical communities | journal = JAMA | volume = 258 | issue = 11 | pages = 1517 | date = September 1987 | pmid = 3306004 | doi = 10.1001/jama.1987.03400110099035 }}</ref> The FDA approved the drug (via the then-new ]) for use against HIV, AIDS, and AIDS Related Complex (ARC, a now-obsolete medical term for pre-AIDS illness) on March 20, 1987.<ref name="Cimons">{{cite news | vauthors = Cimons M | title = U.S. Approves Sale of AZT to AIDS Patients | work = Los Angeles Times | page = 1 | date = March 21, 1987 }}</ref> The time between the first demonstration that AZT was active against HIV in the laboratory and its approval was 25 months.
The triphosphate form also inhibits ] used by human cells to undergo ], but has approximately 100-fold greater affinity for viral reverse transcriptase.<ref name=FurmanPNAS>{{cite journal | author=Furman P, Fyfe J, St Clair M, Weinhold K, Rideout J, Freeman G, Lehrman S, Bolognesi D, Broder S, Mitsuya H | title=Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase | journal=Proc Natl Acad Sci USA | volume=83 | issue=21 | pages=8333–7 | year=1986 | pmid=2430286 | doi=10.1073/pnas.83.21.8333 | pmc=386922}}</ref> Because of this selectivity, ''in vitro'' studies have shown that AZT inhibits HIV replication without affecting the function of normal T cells.<ref name=MitsuyaPNAS/> The cellular DNA polymerase used by ] to replicate is more sensitive to the inhibitory effects of AZT, accounting for its toxic effects on ] and ]s, causing ].<!--
--><ref>{{cite journal | author=Collins M, Sondel N, Cesar D, Hellerstein M | title=Effect of nucleoside reverse transcriptase inhibitors on mitochondrial DNA synthesis in rats and humans | journal=J Acquir Immune Defic Syndr | volume=37 | issue=1 | pages=1132–9 | year=2004 | pmid=15319672 | doi=10.1097/01.qai.0000131585.77530.64}}</ref><!--
--><ref>{{cite journal | author=Parker W, White E, Shaddix S, Ross L, Buckheit R, Germany J, Secrist J, Vince R, Shannon W | title=Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5'-triphosphates of carbovir, 3'-azido-3'-deoxythymidine, 2',3'-dideoxyguanosine and 3'-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs | journal=J Biol Chem | volume=266 | issue=3 | pages=1754–62 | year=1991 | pmid=1703154}}</ref><!--
--><ref>{{cite book | author=Rang H.P., Dale M.M., Ritter J.M. | title=Pharmacology | edition=3<sup>rd</sup> | publisher=Pearson Professional Ltd | year=1995 | isbn=0-443-05974-8}}</ref><!--
--><ref>{{cite journal | author=Balzarini J, Naesens L, Aquaro S, Knispel T, Perno C, De Clercq E, Meier C | title=Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine) | journal=Mol Pharmacol | volume=56 | issue=6 | pages=1354–61 | date=1 December 1999| pmid=10570065 | url=http://molpharm.aspetjournals.org/cgi/content/full/56/6/1354 }}</ref><!--
--><ref name="Yarchoan R, Mitsuya H, Myers C, Broder S 1989 726–38"/>


AZT was subsequently approved unanimously for infants and children in 1990.<ref>AZT Approved for AIDS Children. {{cite news |url=https://www.latimes.com/archives/la-xpm-1990-05-03-mn-603-story.html |title= HEALTH : AZT Approved for AIDS Children |journal=Los Angeles Times |access-date=March 30, 2012 |url-status=live |archive-url=https://web.archive.org/web/20150504000547/http://articles.latimes.com/1990-05-03/news/mn-603_1_azt-approved-for-aids-children |archive-date=May 4, 2015 |date=May 3, 1990 | via = From Times Wire Services}}</ref> AZT was initially administered in significantly higher dosages than today, typically 400&nbsp;mg every four hours, day and night, compared to modern dosage of 300&nbsp;mg twice daily.<ref>{{cite web | url=https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540597/all/Zidovudine__AZT_ | title=Zidovudine (AZT) &#124; Johns Hopkins ABX Guide }}</ref> The paucity of alternatives for treating HIV/AIDS at that time unambiguously affirmed the health risk/benefit ratio, with inevitable slow, disfiguring, and painful death from HIV outweighing the drug's side effect of transient ] and malaise.
==Patent issues==
The patents on AZT have been the target of some controversy. In 1991, ] filed a lawsuit claiming that the patents were invalid. Subsequently, Barr Laboraties and Novopharm Ltd. also challenged the patent, in part based on the assertion that NCI scientists ], ], and ] should have been named as inventors, and those two companies applied to the FDA to sell AZT as a generic drug. In response, Burroughs Wellcome Co. filed a lawsuit against the two companies. The ] ruled in 1992 in favor of ], claiming that even though they had never tested it against HIV, they had conceived of it working before they sent it to the NCI scientists.<ref>{{cite web | url=http://www.law.uh.edu/healthlaw/law/FederalMaterials/FederalCases/BurroughsWellcomevBarrLaboratories.htm | accessdate=2007-02-28 | title=Burroughs Wellcome Co. v. Barr Laboratories, 40 F.3d 1223 (Fed. Cir. 1994) | publisher=University of Houston -- Health Law and Policy Institute | author=US Court of Appeals for the Federal Circuit}}</ref> In 2002, another lawsuit was filed over the patent by the ].


==Society and culture==
However, the ] expired in 2005 (placing AZT in the ]), allowing other drug companies to manufacture and market generic AZT without having to pay ] any royalties. The U.S. FDA has since approved four ] forms of AZT for sale in the U.S.
{{See also|Cost of HIV treatment}}


Until 1991, 80% of the $420 million allocated to the National Institute of Health's AIDS Clinical Trials Group, went toward studies of AZT. Aside from two similarly designed chemotherapies, ddI and ddC, from approval of the drug until 1993, no other drugs against AIDS were approved, leading to criticism that research preoccupation with AZT and its close relatives, and the massive diverting of funds to such, had delayed the development of more efficacious drugs.<ref name="latimes.com"/>
In November 2009 ] formed a joint venture with ] which combined the two companies' HIV assets in one company called ]. This included the rights to Zidovudine.
In 1991, the advocacy group ] filed a lawsuit claiming that the patents were invalid. Subsequently, Barr Laboratories and Novopharm Ltd. also challenged the patent, in part based on the assertion that NCI scientists Samuel Broder, Hiroaki Mitsuya, and Robert Yarchoan should have been named as inventors, and those two companies applied to the FDA to sell AZT as a generic drug. In response, ] Co. filed a lawsuit against the two companies. The ] ruled in 1992 in favor of Burroughs Wellcome, ruling that even though they had never tested it against HIV, they had conceived of it working before they sent it to the NCI scientists. This suit was appealed up to the Supreme Court of the US, but in 1996 the Court declined to formally review it.<ref>{{cite news| vauthors = Greenhouse L | title=Supreme Court Roundup;Justices Reject Challenge Of Patent for AIDS Drug|url=https://www.nytimes.com/1996/01/17/us/supreme-court-roundup-justices-reject-challenge-of-patent-for-aids-drug.html|work=The New York Times|date=January 17, 1996|url-status=live|archive-url=https://web.archive.org/web/20161117145258/http://www.nytimes.com/1996/01/17/us/supreme-court-roundup-justices-reject-challenge-of-patent-for-aids-drug.html|archive-date=November 17, 2016}}</ref> The case, '''', was a landmark in US law of inventorship.<ref>{{cite journal| vauthors = Armstrong M, Murphy Jr GM |title=Inventorship and ownership considerations and pitfalls with collaborative research: patent highlight.|journal=ACS Medicinal Chemistry Letters|date=April 26, 2012|volume=3|issue=5|pages=349–51|pmid=24900477|pmc=4025834|doi=10.1021/ml300084e}}</ref>

In 2002, another lawsuit was filed challenging the patent by the ], which also filed an antitrust case against ].<ref name=Law3602004>{{cite news| vauthors = Meland M |title=Judge Denies Request To Dismiss Patent Challenge Vs. Glaxo's AZT – Law360|url=http://www.law360.com/articles/1396/judge-denies-request-to-dismiss-patent-challenge-vs-glaxo-s-azt|work=Law360|date=May 3, 2004|url-status=live|archive-url=https://web.archive.org/web/20161117212239/http://www.law360.com/articles/1396/judge-denies-request-to-dismiss-patent-challenge-vs-glaxo-s-azt|archive-date=November 17, 2016}}</ref> The patent case was dismissed in 2003 and AHF filed a new case challenging the patent.<ref name=Law3602004/>

GSK's patents on AZT expired in 2005, and in September 2005, the FDA approved three ] versions.<ref>{{cite web|title=HIV/AIDS History of Approvals – HIV/AIDS Historical Time Line 2000 – 2010|url=https://www.fda.gov/ForPatients/Illness/HIVAIDS/History/ucm151081.htm|publisher=U.S. ] (FDA)|date=August 8, 2014|url-status=live|archive-url=https://web.archive.org/web/20161023204558/https://www.fda.gov/ForPatients/Illness/HIVAIDS/History/ucm151081.htm|archive-date=October 23, 2016}}</ref>


==References== ==References==
{{Reflist|45em}} {{Reflist}}


==External links== ==External links==
* * {{cite web| url = https://druginfo.nlm.nih.gov/drugportal/name/zidovudine | publisher = U.S. National Library of Medicine| work = Drug Information Portal| title = Zidovudine }}


{{Antiretroviral drug}}
{{HIVpharm}}
{{GlaxoSmithKline}}
{{Portal bar | Medicine | Viruses }}
{{Authority control}}


]
]
]
] ]
]
]
]
] ]
] ]
] ]
]
]

]
]
]
]
]
]
]
]
]
]
]
]
]
]
]
]
]
]
]